Article type: Letter to Editor
Article
title: Siponimod
in secondary progressive multiple sclerosis
Journal: International
Archives of Health Sciences
Year: 2020
Authors: Jamir Pitton Rissardo, Ana Letícia Fornari
Caprara
E-mail: jamirrissardo@gmail.com
ABSTRACT
Multiple Sclerosis (MS) is an autoimmune disease that affects the central nervous system and is pathologically characterized by chronic inflammation, demyelination, gliosis, and neuronal loss. The epidemiology of this disease defines itself as important, approximately more than three hundred thousand individuals in the United States and two million individuals worldwide have MS. The course may be relapsing-remitting or progressive in nature, divide between primary and secondary. To the diagnosis, the dissemination in time and the dissemination in space need to be assessed. The primary goal in the treatment of multiple sclerosis is to prevent areas of damage by using maintenance therapies also known as disease-modifying therapies. Herein, we would like to discuss siponimod a novel drug approved in March 2019 by the Food and Drug Administration for the clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Full text available at:
DOI
10.4103/iahs.iahs_23_20
Citation
Rissardo JP, Caprara AL. Siponimod in
secondary progressive multiple sclerosis. Int Arch Health Sci 2020;7:155.